Fresh from signing an alliance with Novartis, Chai Discovery has raised $400 million in a third-round financing to support ...

An alarming study has found that people who suffer a serious heart attack are more likely to have micro and nanoplastics ...

Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of ...

What receives far less attention is what happens to the data that was stolen before the encryption even started, and where it ends up in the weeks and months that follow. TrendAI’s latest research ...

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control. In a ...

In this Q&A, Paolo Correale, SVP of global access and pricing at EVERSANA, and Alan Crowther, general manager, global pricing ...

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, showing ...

New biotech Avere Therapeutics has taken a fast-track to becoming a publicly listed company by merging with NextCure, with a ...

Spero Therapeutics has licensed rights to an anti-CD40L antibody developed by China's Innovent Biologics, planning to develop ...

A study has shown that, for people living with advanced cancer, a simple, weekly remote check-in with their care team can ...

As the hype builds around radiopharmaceuticals, Novartis’s Pluvicto (lutetium PSA) remains one of the few that’s actually made it to market. In a conversation at ASCO 2026, Dr Fred Saad of the ...

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5 billion agreement that gives it global rights ...